FindTrial
Sign In

PEG-L-asparaginase

DRUG4 trials

Sponsors

M.D. Anderson Cancer Center, University Hospital Schleswig-Holstein, Dana-Farber Cancer Institute, St. Jude Children's Research Hospital

Conditions

Acute Lymphoid LeukemiaAcute Myeloid LeukemiaLeukemiaLeukemia, Lymphocytic, AcuteMixed Lineage Acute LeukemiaRefractory T-Cell LymphomaRelapsed T-Cell LymphomaT-Cell Lymphoma

Early Phase 1

A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma
TerminatedNCT01878708
Dana-Farber Cancer InstituteRefractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma, T-Cell Lymphoma
Start: 2013-07-31End: 2017-02-28Updated: 2017-03-06

Phase 2

Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage
CompletedNCT00905034
M.D. Anderson Cancer CenterLeukemia, Lymphocytic, Acute
Start: 2009-03-31End: 2015-02-28Updated: 2015-06-29
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
TerminatedNCT02419755
St. Jude Children's Research HospitalAcute Lymphoid Leukemia, Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia
Start: 2015-04-14End: 2016-12-31Updated: 2018-03-07

Phase 3

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
CompletedNCT01117441
University Hospital Schleswig-HolsteinLeukemia
Start: 2010-06-30End: 2021-12-31Updated: 2022-05-24

Related Papers

Unfavorable outcomes in pediatric PAX5r B-cell precursor acute lymphoblastic leukemia: FLT3 targeting as a potential novel treatment strategy
Blood2025-11-03
Multi-omic analysis of early minimal residual disease identifies functional and transcriptomic signatures of treatment resistance in pediatric B-cell acute lymphoblastic leukemia
Blood2025-11-03
<i>Crebbp</i> Mutations Are Associated with Slow Minimal Residual Response to Upfront Induction Chemotherapy in Pediatric High-Hyperdiploid B-Cell Precursor Acute Lymphoblastic Leukemia Treated in the AIEOP-BFM ALL 2009 Protocol
Blood2023-11-02
Effect of two additional doses of intrathecal methotrexate during induction therapy on serious infectious toxicity in pediatric patients with acute lymphoblastic leukemia
Haematologica2023-04-063 citations
Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data.
2021-02-1710 citations
High <i>EVI1</i> Expression due to <i>NRIP1/EVI1</i> Fusion in Therapy‐related Acute Myeloid Leukemia: Description of the First Pediatric Case
HemaSphere2020-09-173 citations
Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol
Blood2019-11-135 citations
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols
Haematologica2019-10-1056 citations
Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen
Haematologica2019-08-0141 citations
Development of Novel Proteasome-HDAC6 Hybrid Inhibitors for Resistant ALL Phenotype
Blood2017-12-07